From in silico target prediction to multi-target drug design: current databases, methods and applications.

Given the tremendous growth of bioactivity databases, the use of computational tools to predict protein targets of small molecules has been gaining importance in recent years. Applications span a wide range, from the 'designed polypharmacology' of compounds to mode-of-action analysis. In this review, we firstly survey databases that can be used for ligand-based target prediction and which have grown tremendously in size in the past. We furthermore outline methods for target prediction that exist, both based on the knowledge of bioactivities from the ligand side and methods that can be applied in situations when a protein structure is known. Applications of successful in silico target identification attempts are discussed in detail, which were based partly or in whole on computational target predictions in the first instance. This includes the authors' own experience using target prediction tools, in this case considering phenotypic antibacterial screens and the analysis of high-throughput screening data. Finally, we will conclude with the prospective application of databases to not only predict, retrospectively, the protein targets of a small molecule, but also how to design ligands with desired polypharmacology in a prospective manner.

[1]  J. Jenkins,et al.  Prediction of Biological Targets for Compounds Using Multiple‐Category Bayesian Models Trained on Chemogenomics Databases. , 2006 .

[2]  C. Wermuth,et al.  Multitargeted drugs: the end of the "one-target-one-disease" philosophy? , 2004, Drug discovery today.

[3]  Jordi Mestres,et al.  SHED: Shannon Entropy Descriptors from Topological Feature Distributions , 2006, J. Chem. Inf. Model..

[4]  P. Bork,et al.  A side effect resource to capture phenotypic effects of drugs , 2010, Molecular systems biology.

[5]  K. Fidelis,et al.  Interaction Model Based on Local Protein Substructures Generalizes to the Entire Structural Enzyme‐Ligand Space. , 2009 .

[6]  V. Poroikov,et al.  Top 200 Medicines: Can New Actions be Discovered Through Computer-aided Prediction? , 2001, SAR and QSAR in environmental research.

[7]  Zhe Shi,et al.  Computer Aided Multi-target Drug Design, Multi-target Virtual Screening , 2010 .

[8]  J. Dearden,et al.  Design of new cognition enhancers: from computer prediction to synthesis and biological evaluation. , 2004, Journal of medicinal chemistry.

[9]  C. E. Peishoff,et al.  A critical assessment of docking programs and scoring functions. , 2006, Journal of medicinal chemistry.

[10]  Andreas Bender,et al.  Ligand-Target Prediction Using Winnow and Naive Bayesian Algorithms and the Implications of Overall Performance Statistics , 2008, J. Chem. Inf. Model..

[11]  J. Lamerdin,et al.  Identifying off-target effects and hidden phenotypes of drugs in human cells , 2006, Nature chemical biology.

[12]  Christophe Chipot,et al.  Free Energy Calculations in Biological Systems. How Useful Are They in Practice , 2006 .

[13]  Michael J. Keiser,et al.  Predicting new molecular targets for known drugs , 2009, Nature.

[14]  Judith M. Rollinger,et al.  Accessing target information by virtual parallel screening—The impact on natural product research , 2009 .

[15]  Xin Wen,et al.  BindingDB: a web-accessible database of experimentally determined protein–ligand binding affinities , 2006, Nucleic Acids Res..

[16]  Xiaomin Luo,et al.  PDTD: a web-accessible protein database for drug target identification , 2008, BMC Bioinformatics.

[17]  Didier Rognan,et al.  In silico-guided target identification of a scaffold-focused library: 1,3,5-triazepan-2,6-diones as novel phospholipase A2 inhibitors. , 2006, Journal of medicinal chemistry.

[18]  R. Glen,et al.  Molecular similarity: a key technique in molecular informatics. , 2004, Organic & biomolecular chemistry.

[19]  J. Mestres,et al.  A ligand-based approach to mining the chemogenomic space of drugs. , 2008, Combinatorial chemistry & high throughput screening.

[20]  Simon K. Mencher,et al.  Promiscuous drugs compared to selective drugs (promiscuity can be a virtue) , 2005, BMC clinical pharmacology.

[21]  A. Fliri,et al.  Biological spectra analysis: Linking biological activity profiles to molecular structure. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[22]  K. Chou,et al.  Predicting Drug-Target Interaction Networks Based on Functional Groups and Biological Features , 2010, PloS one.

[23]  Didier Rognan,et al.  Structure‐Based Approaches to Target Fishing and Ligand Profiling , 2010, Molecular informatics.

[24]  Richard M. Jackson,et al.  ReverseScreen3D: A Structure-Based Ligand Matching Method To Identify Protein Targets , 2011, J. Chem. Inf. Model..

[25]  Camille G Wermuth,et al.  Selective optimization of side activities: the SOSA approach. , 2006, Drug discovery today.

[26]  H. Kubinyi Drug research: myths, hype and reality , 2003, Nature Reviews Drug Discovery.

[27]  J. Berg,et al.  Molecular dynamics simulations of biomolecules , 2002, Nature Structural Biology.

[28]  Edda Klipp,et al.  Biochemical network-based drug-target prediction. , 2010, Current opinion in biotechnology.

[29]  R. Morphy Selectively nonselective kinase inhibition: striking the right balance. , 2010, Journal of medicinal chemistry.

[30]  John A. Tallarico,et al.  Use of ligand based models for protein domains to predict novel molecular targets and applications to triage affinity chromatography data. , 2009, Journal of proteome research.

[31]  David L. Mobley,et al.  Chapter 4 Alchemical Free Energy Calculations: Ready for Prime Time? , 2007 .

[32]  Kai Huang,et al.  PharmMapper server: a web server for potential drug target identification using pharmacophore mapping approach , 2010, Nucleic Acids Res..

[33]  A. Fliri,et al.  Analysis of drug-induced effect patterns to link structure and side effects of medicines , 2005, Nature chemical biology.

[34]  Vladimir Poroikov,et al.  QSAR Modelling of Rat Acute Toxicity on the Basis of PASS Prediction , 2011, Molecular informatics.

[35]  Y. Martin,et al.  Do structurally similar molecules have similar biological activity? , 2002, Journal of medicinal chemistry.

[36]  Petra Schneider,et al.  Self-organizing molecular fingerprints: a ligand-based view on drug-like chemical space and off-target prediction. , 2009, Future medicinal chemistry.

[37]  Daniela Schuster,et al.  3D pharmacophores as tools for activity profiling. , 2010, Drug discovery today. Technologies.

[38]  Andreas Bender,et al.  Databases: Compound bioactivities go public , 2010 .

[39]  A. Bender,et al.  Analysis of Pharmacology Data and the Prediction of Adverse Drug Reactions and Off‐Target Effects from Chemical Structure , 2007, ChemMedChem.

[40]  Andreas Bender,et al.  Molecular Similarity Searching Using Atom Environments, Information-Based Feature Selection, and a Naïve Bayesian Classifier , 2004, J. Chem. Inf. Model..

[41]  Péter Csermely,et al.  The efficiency of multi-target drugs: the network approach might help drug design. , 2004, Trends in pharmacological sciences.

[42]  Jean-Loup Faulon,et al.  Genome scale enzyme–metabolite and drug–target interaction predictions using the signature molecular descriptor , 2008 .

[43]  Y.Z. Chen,et al.  Ligand–protein inverse docking and its potential use in the computer search of protein targets of a small molecule , 2001, Proteins.

[44]  Peter G. Schultz,et al.  In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen , 2008, Proceedings of the National Academy of Sciences.

[45]  E. Fischer Einfluss der Configuration auf die Wirkung der Enzyme , 1894 .

[46]  Andreas Bender,et al.  Computational methods to support high-content screening: from compound selection and data analysis to postulating target hypotheses , 2009, Expert opinion on drug discovery.

[47]  Yanli Wang,et al.  PubChem: a public information system for analyzing bioactivities of small molecules , 2009, Nucleic Acids Res..

[48]  Andreas Bender,et al.  Understanding False Positives in Reporter Gene Assays: in Silico Chemogenomics Approaches To Prioritize Cell-Based HTS Data , 2007, J. Chem. Inf. Model..

[49]  Andreas Bender,et al.  How Similar Are Similarity Searching Methods? A Principal Component Analysis of Molecular Descriptor Space , 2009, J. Chem. Inf. Model..

[50]  John A. Tallarico,et al.  Multi-parameter phenotypic profiling: using cellular effects to characterize small-molecule compounds , 2009, Nature Reviews Drug Discovery.

[51]  Dariusz Plewczynski,et al.  Target specific compound identification using a support vector machine. , 2007, Combinatorial chemistry & high throughput screening.

[52]  Gerard J. P. van Westen,et al.  Proteochemometric modeling as a tool to design selective compounds and for extrapolating to novel targets , 2011 .

[53]  Andreas Bender,et al.  Flexible 3D pharmacophores as descriptors of dynamic biological space. , 2007, Journal of molecular graphics & modelling.

[54]  J. Epplen,et al.  Indirect gene diagnoses for complex (multifactorial) diseases--a review. , 1995, Gene.

[55]  Andreas Bender,et al.  "Bayes Affinity Fingerprints" Improve Retrieval Rates in Virtual Screening and Define Orthogonal Bioactivity Space: When Are Multitarget Drugs a Feasible Concept? , 2006, J. Chem. Inf. Model..

[56]  Raúl Toral,et al.  RED: A Set of Molecular Descriptors Based on Re'nyi Entropy , 2009, J. Chem. Inf. Model..

[57]  G. V. Paolini,et al.  Global mapping of pharmacological space , 2006, Nature Biotechnology.

[58]  Roman A Zubarev,et al.  Drug target identification from protein dynamics using quantitative pathway analysis. , 2011, Journal of proteome research.

[59]  David S. Wishart,et al.  DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..

[60]  Thierry Langer,et al.  Parallel Screening and Activity Profiling with HIV Protease Inhibitor Pharmacophore Models , 2007, J. Chem. Inf. Model..

[61]  Shigeyuki Yokoyama,et al.  In silico functional profiling of small molecules and its applications. , 2008, Journal of medicinal chemistry.

[62]  Y. Z. Chen,et al.  Database of traditional Chinese medicine and its application to studies of mechanism and to prescription validation , 2006, British journal of pharmacology.

[63]  Stefan H. E. Kaufmann,et al.  Paul Ehrlich: founder of chemotherapy , 2008, Nature Reviews Drug Discovery.

[64]  Jordi Mestres,et al.  Computational chemogenomics approaches to systematic knowledge-based drug discovery. , 2004, Current opinion in drug discovery & development.

[65]  Bernhard Kuster,et al.  Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors , 2007, Nature Biotechnology.

[66]  Vladimir Poroikov,et al.  Multi-targeted natural products evaluation based on biological activity prediction with PASS. , 2010, Current pharmaceutical design.

[67]  Thierry Langer,et al.  In silico Target Fishing for Rationalized Ligand Discovery Exemplified on Constituents of Ruta graveolens , 2008, Planta medica.

[68]  A. Bender,et al.  In silico target fishing: Predicting biological targets from chemical structure , 2006 .

[69]  Michael J. Keiser,et al.  Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.

[70]  Michael T. M. Emmerich,et al.  A novel chemogenomics analysis of G protein-coupled receptors (GPCRs) and their ligands: a potential strategy for receptor de-orphanization , 2010, BMC Bioinformatics.

[71]  Yi Wang,et al.  In silico search of putative adverse drug reaction related proteins as a potential tool for facilitating drug adverse effect prediction. , 2006, Toxicology letters.

[72]  Philip E. Bourne,et al.  PROMISCUOUS: a database for network-based drug-repositioning , 2010, Nucleic Acids Res..

[73]  Richard Morphy,et al.  Designed Multiple Ligands. An Emerging Drug Discovery Paradigm , 2006 .

[74]  D. Horvath,et al.  G-protein-coupled receptor affinity prediction based on the use of a profiling dataset: QSAR design, synthesis, and experimental validation. , 2005, Journal of medicinal chemistry.

[75]  Adriaan P. IJzerman,et al.  Substructure Mining of GPCR Ligands Reveals Activity-Class Specific Functional Groups in an Unbiased Manner , 2009, J. Chem. Inf. Model..

[76]  A. Hopkins Network pharmacology , 2007, Nature Biotechnology.

[77]  Thierry Langer,et al.  Development and validation of an in silico P450 profiler based on pharmacophore models. , 2006, Current drug discovery technologies.

[78]  Jürgen Bajorath,et al.  Combining Horizontal and Vertical Substructure Relationships in Scaffold Hierarchies for Activity Prediction , 2011, J. Chem. Inf. Model..

[79]  T. Klabunde,et al.  GPCR Antitarget Modeling: Pharmacophore Models for Biogenic Amine Binding GPCRs to Avoid GPCR‐Mediated Side Effects , 2005, Chembiochem : a European journal of chemical biology.

[80]  Xiaobo Zhou,et al.  Predicting enzyme targets for cancer drugs by profiling human Metabolic reactions in NCI-60 cell lines , 2010, BMC Bioinformatics.

[81]  L. Meijer,et al.  Inverse in silico screening for identification of kinase inhibitor targets. , 2007, Chemistry & biology.

[82]  John A. Tallarico,et al.  Integrating high-content screening and ligand-target prediction to identify mechanism of action. , 2008, Nature chemical biology.

[83]  Woody Sherman,et al.  Large-Scale Systematic Analysis of 2D Fingerprint Methods and Parameters to Improve Virtual Screening Enrichments , 2010, J. Chem. Inf. Model..

[84]  J. A. Bush,et al.  Method for relating the structure and properties of chemical compounds , 1974, Nature.

[85]  C. Mattingly,et al.  The Comparative Toxicogenomics Database (CTD). , 2003, Environmental health perspectives.

[86]  D. Barlow,et al.  In silico search for multi-target anti-inflammatories in Chinese herbs and formulas. , 2010, Bioorganic & medicinal chemistry.

[87]  George Karypis,et al.  Target Fishing for Chemical Compounds Using Target-Ligand Activity Data and Ranking Based Methods , 2009, J. Chem. Inf. Model..

[88]  Mark A. Ragan,et al.  A Semantic Web Ontology for Small Molecules and Their Biological Targets , 2010, J. Chem. Inf. Model..

[89]  V. Poroikov,et al.  PASS: identification of probable targets and mechanisms of toxicity , 2007, SAR and QSAR in environmental research.

[90]  Ariel Fernández,et al.  Turning promiscuous kinase inhibitors into safer drugs. , 2008, Trends in biotechnology.

[91]  Martin Serrano,et al.  Nucleic Acids Research Advance Access published October 18, 2007 ChemBank: a small-molecule screening and , 2007 .

[92]  Shiwen Zhao,et al.  Network-Based Relating Pharmacological and Genomic Spaces for Drug Target Identification , 2010, PloS one.

[93]  J. Mestres,et al.  In Silico Receptorome Screening of Antipsychotic Drugs , 2010, Molecular informatics.

[94]  Janet M Thornton,et al.  Ligand selectivity and competition between enzymes in silico , 2004, Nature Biotechnology.

[95]  A. Bender,et al.  Modeling Promiscuity Based on in vitro Safety Pharmacology Profiling Data , 2007, ChemMedChem.

[96]  P. Marks,et al.  Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors , 1999, Nature.

[97]  R. Solé,et al.  The topology of drug-target interaction networks: implicit dependence on drug properties and target families. , 2009, Molecular bioSystems.

[98]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[99]  Yoshihiro Yamanishi,et al.  Supervised prediction of drug–target interactions using bipartite local models , 2009, Bioinform..

[100]  Michael J. Keiser,et al.  Prediction and evaluation of protein farnesyltransferase inhibition by commercial drugs. , 2010, Journal of medicinal chemistry.

[101]  T. Lundstedt,et al.  Development of proteo-chemometrics: a novel technology for the analysis of drug-receptor interactions. , 2001, Biochimica et biophysica acta.

[102]  Z. Deng,et al.  Bridging chemical and biological space: "target fishing" using 2D and 3D molecular descriptors. , 2006, Journal of medicinal chemistry.

[103]  O. Westphal,et al.  Paul Ehrlich--in search of the magic bullet. , 2004, Microbes and infection.

[104]  Thierry Langer,et al.  Parallel Screening: A Novel Concept in Pharmacophore Modeling and Virtual Screening , 2006, J. Chem. Inf. Model..

[105]  Mindy I. Davis,et al.  A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.

[106]  T. Pruett Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America , 2010 .

[107]  Michael A. King,et al.  The configurational dependence of binding free energies: A Poisson–Boltzmann study of Neuraminidase inhibitors , 2001, J. Comput. Aided Mol. Des..

[108]  Anthony J Williams,et al.  Public chemical compound databases. , 2008, Current opinion in drug discovery & development.

[109]  Bryan L Roth,et al.  Screening the receptorome to discover the molecular targets for plant-derived psychoactive compounds: a novel approach for CNS drug discovery. , 2004, Pharmacology & therapeutics.

[110]  Didier Rognan,et al.  Comparative evaluation of eight docking tools for docking and virtual screening accuracy , 2004, Proteins.

[111]  André Schrattenholz,et al.  Systems biology approaches and tools for analysis of interactomes and multi-target drugs. , 2010, Methods in molecular biology.

[112]  Oliver Ebenhöh,et al.  Ground State Robustness as an Evolutionary Design Principle in Signaling Networks , 2009, PloS one.

[113]  Andreas Bender,et al.  How similar are those molecules after all? Use two descriptors and you will have three different answers , 2010, Expert opinion on drug discovery.

[114]  Peter A. Kollman,et al.  FREE ENERGY CALCULATIONS : APPLICATIONS TO CHEMICAL AND BIOCHEMICAL PHENOMENA , 1993 .

[115]  Y. Z. Chen,et al.  Prediction of potential toxicity and side effect protein targets of a small molecule by a ligand-protein inverse docking approach. , 2001, Journal of molecular graphics & modelling.

[116]  Robert B. Russell,et al.  SuperTarget and Matador: resources for exploring drug-target relationships , 2007, Nucleic Acids Res..

[117]  Jordi Mestres,et al.  A General Analysis of Field-Based Molecular Similarity Indices , 2002 .

[118]  M. Yoshida,et al.  Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. , 1993, The Journal of biological chemistry.

[119]  Richard Morphy,et al.  Designing multiple ligands - medicinal chemistry strategies and challenges. , 2009, Current pharmaceutical design.

[120]  Bin Chen,et al.  Chem2Bio2RDF: a semantic framework for linking and data mining chemogenomic and systems chemical biology data , 2010, BMC Bioinformatics.

[121]  S. Giordano,et al.  From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. , 2008, Current medicinal chemistry.

[122]  Mona Singh,et al.  Toward the dynamic interactome: it's about time , 2010, Briefings Bioinform..

[123]  David S. Wishart,et al.  T3DB: a comprehensively annotated database of common toxins and their targets , 2009, Nucleic Acids Res..

[124]  Choong Yong Ung,et al.  Can an in silico Drug‐Target Search Method Be Used to Probe Potential Mechanism of Medicinal Plant Ingredients? , 2003 .

[125]  Andreas Bender,et al.  “Plate Cherry Picking”: A Novel Semi-Sequential Screening Paradigm for Cheaper, Faster, Information-Rich Compound Selection , 2007, Journal of biomolecular screening.

[126]  Boon Chuan Low,et al.  In-Silico Approaches to Multi-target Drug Discovery , 2010, Pharmaceutical Research.

[127]  Lei Chen,et al.  Prediction of interactiveness between small molecules and enzymes by combining gene ontology and compound similarity , 2009, J. Comput. Chem..

[128]  Richard Morphy,et al.  From magic bullets to designed multiple ligands. , 2004, Drug discovery today.

[129]  P. Clemons,et al.  Chemogenomic data analysis: prediction of small-molecule targets and the advent of biological fingerprint. , 2007, Combinatorial chemistry & high throughput screening.

[130]  Thierry Langer,et al.  LigandScout: 3-D Pharmacophores Derived from Protein-Bound Ligands and Their Use as Virtual Screening Filters , 2005, J. Chem. Inf. Model..

[131]  Gerald M. Maggiora,et al.  On Outliers and Activity Cliffs-Why QSAR Often Disappoints , 2006, J. Chem. Inf. Model..

[132]  Daniela Schuster,et al.  Predicting cyclooxygenase inhibition by three-dimensional pharmacophoric profiling. Part II: Identification of enzyme inhibitors from Prasaplai, a Thai traditional medicine , 2011, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[133]  José D Faraldo-Gómez,et al.  Molecular Mechanism of Selective Recruitment of Syk Kinases by the Membrane Antigen-Receptor Complex* , 2011, The Journal of Biological Chemistry.

[134]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[135]  E. Jacoby,et al.  Chemogenomic strategies to expand the bioactive chemical space. , 2009, Current medicinal chemistry.

[136]  J. Olivero-Verbel,et al.  Theoretical targets for TCDD: a bioinformatics approach. , 2010, Chemosphere.

[137]  C. Harris,et al.  Chemogenomics: structuring the drug discovery process to gene families. , 2006, Drug discovery today.

[138]  David Selwood,et al.  Imatinib binding and cKIT inhibition is abrogated by the cKIT kinase domain I missense mutation Val654Ala , 2005, Molecular Cancer Therapeutics.

[139]  Y. Shoenfeld,et al.  Antiinflammatory and immunomodulatory properties of statins , 2002, Immunologic research.

[140]  Roger A. Sayle,et al.  So you think you understand tautomerism? , 2010, J. Comput. Aided Mol. Des..

[141]  Xiaohua Ma,et al.  Mechanisms of drug combinations: interaction and network perspectives , 2009, Nature Reviews Drug Discovery.

[142]  Jean-Philippe Vert,et al.  Virtual screening of GPCRs: An in silico chemogenomics approach , 2008, BMC Bioinformatics.

[143]  P. Bork,et al.  Large‐scale prediction of drug–target relationships , 2008, FEBS letters.

[144]  X. Chen,et al.  TTD: Therapeutic Target Database , 2002, Nucleic Acids Res..

[145]  Thomas Bäck,et al.  Combining Aggregation with Pareto Optimization: A Case Study in Evolutionary Molecular Design , 2009, EMO.

[146]  David M. Rocke,et al.  Predicting ligand binding to proteins by affinity fingerprinting. , 1995, Chemistry & biology.

[147]  Nathanael Weill,et al.  Development and Validation of a Novel Protein-Ligand Fingerprint To Mine Chemogenomic Space: Application to G Protein-Coupled Receptors and Their Ligands , 2009, J. Chem. Inf. Model..

[148]  Pekka Tiikkainen,et al.  Critical Comparison of Virtual Screening Methods against the MUV Data Set , 2009, J. Chem. Inf. Model..

[149]  Andreas Bender,et al.  Fishing the target of antitubercular compounds: in silico target deconvolution model development and validation. , 2009, Journal of proteome research.

[150]  Pei Zhou,et al.  Structure of the deacetylase LpxC bound to the antibiotic CHIR-090: Time-dependent inhibition and specificity in ligand binding , 2007, Proceedings of the National Academy of Sciences.

[151]  José L. Medina-Franco,et al.  Characterization of Activity Landscapes Using 2D and 3D Similarity Methods: Consensus Activity Cliffs , 2009, J. Chem. Inf. Model..

[152]  John M. Barnard,et al.  Chemical Similarity Searching , 1998, J. Chem. Inf. Comput. Sci..

[153]  M. Ashburner,et al.  Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.

[154]  V. Poroikov,et al.  Computer-aided prediction for medicinal chemistry via the Internet , 2008, SAR and QSAR in environmental research.